Nine-Year Follow-Up of Interleukin 6 in Chronic Obstructive Pulmonary Disease – Complementary Results from Previous Studies

References

• Prudente RA, Tanni SE. Interleucina 6 de pacientes com DPOC em nove anos; 2020.
   Google Scholar
• Prudente R, Mesquita C, Franco E, Ferrari R, Godoy I, Tanni S. Role of interleukin 6 in COPD patients over nine years. Eur Respir J. 2020;56:2471. doi:10.1183/13993003.congress-2020.2471.
   Web of Science ®Google Scholar
• Singh D, Agusti A, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. Eur Respir J. 2019;53(5):1900164. doi:10.1183/13993003.00164-2019
   PubMed Web of Science ®Google Scholar
• Wouters EFM. Local and systemic inflammation in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2(1):26–33. doi:10.1513/pats.200408-039MS
   PubMedGoogle Scholar
• Dourado VZ, Tanni SE, Vale SA, Faganello MM, Sanchez FF, Godoy I. Manifestações sistêmicas na doença pulmonar obstrutiva crônica. J Bras Pneumol. 2006;32(2):161–171. doi:10.1590/S1806-37132006000200012
   PubMedGoogle Scholar
• Rabe KF, Beghé B, Luppi F, Fabbri LM. Update in chronic obstructive pulmonary disease 2006. Am J Respir Crit Care Med. 2007;175(12):1222–1232. doi:10.1164/rccm.200704-586UP
   PubMed Web of Science ®Google Scholar
• Ahmadi-Abhari S, Kaptoge S, Luben RN, Wareham NJ, Khaw KT. Longitudinal association of C-reactive protein and lung function over 13 years: the EPIC-Norfolk Study. Am J Epidemiol. 2014;179(1):48–56. doi:10.1093/aje/kwt208
   PubMed Web of Science ®Google Scholar
• MacNee W. Pulmonary and systemic oxidant/antioxidant imbalance in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2:50–60. doi:10.1513/pats.200411-056SF.
   PubMedGoogle Scholar
• Agustí A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One. 2012;7(5):e37483. doi:10.1371/journal.pone.0037483
   PubMed Web of Science ®Google Scholar
• Ferrari R, Tanni SE, Caram LMO, Corrêa C, Corrêa CR, Godoy I. Three-year follow-up of Interleukin 6 and C-reactive protein in chronic obstructive pulmonary disease. Respir Res. 2013;14(1):24. doi:10.1186/1465-9921-14-24
   PubMedGoogle Scholar
• Smith BM, Jensen D, Brosseau M, Benedetti A, Coxson HO, Bourbeau J. Impact of pulmonary emphysema on exercise capacity and its physiological determinants in chronic obstructive pulmonary disease. Sci Rep. 2018;8(1). doi:10.1038/s41598-018-34014-5
   Web of Science ®Google Scholar
• Garudadri S, Woodruff PG, Han MLK, et al. Systemic markers of inflammation in smokers with symptoms despite preserved spirometry in SPIROMICS. Chest. 2019;155(5):908–917. doi:10.1016/j.chest.2018.12.022
   PubMed Web of Science ®Google Scholar
• Souza JRM, Oliveira RT, Blotta MHSL, Coelho OR. Níveis séricos de interleucina-6 (IL-6), interleucina-18 (IL-18) e proteína C reativa (PCR) na síndrome coronariana aguda sem supradesnivelamento do ST em pacientes com diabete tipo 2. Arq Bras Cardiol. 2008;90(2):94–99. doi:10.1590/S0066-782X2008000200004
   Google Scholar
• Shapiro SD. Evolving concepts in the pathogenesis of chronic obstructive pulmonary disease. Clin Chest Med. 2000;21(4):621–632. doi:10.1016/S0272-5231(05)70172-6
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J. 2003;22(4):672–688. doi:10.1183/09031936.03.00040703
   PubMed Web of Science ®Google Scholar
• Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128–1138. doi:10.1056/nejmoa0909883
   PubMed Web of Science ®Google Scholar
• Menezes AMB, Jardim JR, Pérez-Padilla R, et al. Prevalence of chronic obstructive pulmonary disease and associated factors: the PLATINO Study in São Paulo, Brazil. Cad Saude Publica. 2005;21(5). doi:10.1590/S0102-311X2005000500030
   Google Scholar
• Faganello MM, Tanni SE, Sanchez FF, Pelegrino NRG, Lucheta PA, Godoy I. BODE index and GOLD staging as predictors of 1-year exacerbation risk in chronic obstructive pulmonary disease. Am J Med Sci. 2010;339(1):10–14. doi:10.1097/MAJ.0b013e3181bb8111
   PubMed Web of Science ®Google Scholar
• Ferrari R, Tanni SE, Faganello MM, Caram LMO, Lucheta PA, Godoy I. Three-year follow-up study of respiratory and systemic manifestations of chronic obstructive pulmonary disease. Braz J Med Biol Res. 2011;44(1):46–52. doi:10.1590/S0100-879X2010007500150
   PubMed Web of Science ®Google Scholar
• Moreira GL, Manzano BM, Gazzotti MR, et al. PLATINO, estudo de seguimento de nove anos sobre DPOC na cidade de São Paulo: o problema do subdiagnóstico. J Bras Pneumol. 2014;40(1):30–37. doi:10.1590/S1806-37132014000100005
   PubMedGoogle Scholar
• Tanni SE, Zamuner ATS, Coelho LS, Vale SA, Godoy I, Paiva SAR. Are metabolic syndrome and its components associated with 5-year mortality in chronic obstructive pulmonary disease patients? Metab Syndr Relat Disord. 2015;13(1):52–54. doi:10.1089/met.2014.0100
   PubMed Web of Science ®Google Scholar
• Prudente R, Franco EAT, Mesquita CB, Ferrari R, De godoy I, Tanni SE. Predictors of mortality in patients with COPD after 9 years. Int J COPD. 2018;13:3389–3398. doi:10.2147/COPD.S174665
   Google Scholar
• Marchioro J, Gazzotti MR, Moreira GL, et al. Anthropometric status of individuals with COPD in the city of São Paulo, Brazil, over time-analysis of a population-based study. J Bras Pneumol. 2019;45(6). doi:10.1590/1806-3713/e20170157
   PubMed Web of Science ®Google Scholar
• Prudente R, Ferrari R, Mesquita CB, et al. Peripheral blood eosinophils and nine years mortality in COPD patients. Int J COPD. 2021;16:979–985. doi:10.2147/COPD.S265275
   Google Scholar
• Wei J, Xiong XF, Lin YH, Zheng BX, Cheng DY. Association between serum interleukin-6 concentrations and chronic obstructive pulmonary disease: a systematic review and meta-analysis. PeerJ. 2015;2015(8):e1199. doi:10.7717/peerj.1199
   Web of Science ®Google Scholar
• Garcia-Rio F, Miravitlles M, Soriano JB, et al. Systemic inflammation in chronic obstructive pulmonary disease: a population-based study. Respir Res. 2010;11(1):1–5. doi:10.1186/1465-9921-11-63
   PubMedGoogle Scholar
• Jakeways N, McKeever T, Lewis SA, Weiss ST, Britton J. Relationship between FEV1 reduction and respiratory symptoms in the general population. Eur Respir J. 2003;21(4):658–663. doi:10.1183/09031936.03.00069603
   PubMed Web of Science ®Google Scholar
• Tantucci C, Modina D. Lung function decline in COPD. Int J COPD. 2012;(7):95. doi:10.2147/COPD.S27480
   Google Scholar
• Mehrotra N, Freire AX, Bauer DC, et al. Predictors of mortality in elderly subjects with obstructive airway disease: the PILE Score. Ann Epidemiol. 2010;20(3):223–232. doi:10.1016/j.annepidem.2009.11.005
   PubMed Web of Science ®Google Scholar
• Celli BR, Locantore N, Yates J, et al. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;185(10):1065–1072. doi:10.1164/rccm.201110-1792OC
   PubMed Web of Science ®Google Scholar
• Pinto-Plata V, Casanova C, Müllerova H, et al. Inflammatory and repair serum biomarker pattern. Association to clinical outcomes in COPD. Respir Res. 2012;13(1):71. doi:10.1186/1465-9921-13-71
   PubMedGoogle Scholar
• Fermont JM, Masconi KL, Jensen MT, et al. Biomarkers and clinical outcomes in COPD: a systematic review and meta-analysis. Thorax. 2019;74(5):439–446. doi:10.1136/thoraxjnl-2018-211855
   PubMed Web of Science ®Google Scholar
• Nunes LN, Klück MM, Fachel JMG. Multiple imputations for missing data: a simulation with epidemiological data. Cad Saude Publica. 2009;25(2):268–278. doi:10.1590/s0102-311x2009000200005
   PubMed Web of Science ®Google Scholar
• Khan NA, Daga MK, Ahmad I, et al. Evaluation of BODE index and its relationship with systemic inflammation mediated by proinflammatory biomarkers in patients with COPD. J Inflamm Res. 2016;9:187–198. doi:10.2147/JIR.S108783
   PubMedGoogle Scholar
• Sørensen AK, Holmgaard DB, Mygind LH, Johansen J, Pedersen C. Neutrophil-to-lymphocyte ratio, calprotectin and YKL-40 in patients with chronic obstructive pulmonary disease: correlations and 5-year mortality - A cohort study. J Inflamm. 2015;12(1):1–2. doi:10.1186/s12950-015-0064-5
   Google Scholar
• Acanfora D, Scicchitano P, Carone M, et al. Relative lymphocyte count as an indicator of 3-year mortality in elderly people with severe COPD. BMC Pulm Med. 2018;18(1):1–8. doi:10.1186/s12890-018-0685-6
   PubMedGoogle Scholar
• Xiong W, Xu M, Zhao Y, Wu X, Pudasaini B, Liu JM. Can we predict the prognosis of COPD with a routine blood test? Int J COPD. 2017;12:615–625. doi:10.2147/COPD.S124041
   Google Scholar
• Lee H, Um SJ, Kim YS, et al. Association of the neutrophil-to-lymphocyte ratio with lung function and exacerbations in patients with chronic obstructive pulmonary disease. PLoS One. 2016;11(6):e0156511. doi:10.1371/journal.pone.0156511
   PubMed Web of Science ®Google Scholar